DAIICHI SANKYO CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,773 JPY | +3.55% |
|
+6.93% | +49.10% |
| Jun. 04 | Daiichi Sankyo Buys Back Shares Worth Over 29 Billion Yen in May | MT |
| Jun. 03 | AstraZeneca Says Potential Breast Cancer Treatment Reduces Risk of Disease Progression by up to 38% | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Calendar
2024-07-30
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
5,575
JPY
Average target price
6,010
JPY
Spread / Average Target
+7.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +49.10% | 68.23B | |
| +42.69% | 749B | |
| +38.79% | 605B | |
| -6.87% | 351B | |
| +18.74% | 328B | |
| +6.76% | 292B | |
| +18.66% | 248B | |
| -2.54% | 214B | |
| +11.29% | 216B | |
| +2.64% | 167B |
- Stock Market
- Equities
- 4568 Stock
- News Daiichi Sankyo Co., Ltd.
- Esperion, Daiichi Get EU Committee Recommendation For Nilemdo, Nustendi Label Update
